vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and OHIO VALLEY BANC CORP (OVBC). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $16.2M, roughly 1.2× OHIO VALLEY BANC CORP). OHIO VALLEY BANC CORP runs the higher net margin — 24.4% vs -177.4%, a 201.8% gap on every dollar of revenue. On growth, OHIO VALLEY BANC CORP posted the faster year-over-year revenue change (-4.6% vs -11.5%). OHIO VALLEY BANC CORP produced more free cash flow last quarter ($17.0M vs $-23.1M). Over the past eight quarters, OHIO VALLEY BANC CORP's revenue compounded faster (4.3% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Valley National Bank of Arizona was a bank based in Phoenix, Arizona, founded in 1900 and acquired by Bank One in 1992. The bank was one of Arizona's leading financial institutions during the 20th century and the last major independent bank in Arizona at the time of its acquisition.

LAB vs OVBC — Head-to-Head

Bigger by revenue
LAB
LAB
1.2× larger
LAB
$19.6M
$16.2M
OVBC
Growing faster (revenue YoY)
OVBC
OVBC
+6.8% gap
OVBC
-4.6%
-11.5%
LAB
Higher net margin
OVBC
OVBC
201.8% more per $
OVBC
24.4%
-177.4%
LAB
More free cash flow
OVBC
OVBC
$40.1M more FCF
OVBC
$17.0M
$-23.1M
LAB
Faster 2-yr revenue CAGR
OVBC
OVBC
Annualised
OVBC
4.3%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
LAB
LAB
OVBC
OVBC
Revenue
$19.6M
$16.2M
Net Profit
$-34.7M
$4.0M
Gross Margin
48.5%
Operating Margin
-168.5%
30.7%
Net Margin
-177.4%
24.4%
Revenue YoY
-11.5%
-4.6%
Net Profit YoY
-28.8%
57.3%
EPS (diluted)
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
OVBC
OVBC
Q4 25
$16.2M
Q3 25
$19.6M
$16.3M
Q2 25
$21.8M
$17.4M
Q1 25
$40.8M
$16.8M
Q4 24
$17.0M
Q3 24
$22.1M
$15.4M
Q2 24
$22.5M
$14.7M
Q1 24
$45.5M
$14.9M
Net Profit
LAB
LAB
OVBC
OVBC
Q4 25
$4.0M
Q3 25
$-34.7M
$3.0M
Q2 25
$-33.5M
$4.2M
Q1 25
$-26.0M
$4.4M
Q4 24
$2.5M
Q3 24
$-26.9M
$2.7M
Q2 24
$-45.7M
$3.0M
Q1 24
$-32.2M
$2.8M
Gross Margin
LAB
LAB
OVBC
OVBC
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
OVBC
OVBC
Q4 25
30.7%
Q3 25
-168.5%
22.9%
Q2 25
-118.1%
29.8%
Q1 25
-80.8%
33.1%
Q4 24
18.1%
Q3 24
-120.9%
21.3%
Q2 24
-134.5%
24.7%
Q1 24
-132.2%
22.8%
Net Margin
LAB
LAB
OVBC
OVBC
Q4 25
24.4%
Q3 25
-177.4%
18.5%
Q2 25
-153.7%
24.2%
Q1 25
-63.8%
26.2%
Q4 24
14.8%
Q3 24
-122.0%
17.6%
Q2 24
-203.3%
20.3%
Q1 24
-70.6%
18.8%
EPS (diluted)
LAB
LAB
OVBC
OVBC
Q4 25
Q3 25
$-0.09
Q2 25
$-0.09
Q1 25
$-0.07
Q4 24
Q3 24
$-0.07
Q2 24
$-0.12
Q1 24
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
OVBC
OVBC
Cash + ST InvestmentsLiquidity on hand
$129.4M
$45.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$170.3M
Total Assets
$539.6M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
OVBC
OVBC
Q4 25
$45.9M
Q3 25
$129.4M
$89.3M
Q2 25
$158.6M
$54.6M
Q1 25
$150.9M
$120.6M
Q4 24
$83.1M
Q3 24
$210.6M
$82.2M
Q2 24
$269.8M
$107.7M
Q1 24
$287.1M
$129.1M
Total Debt
LAB
LAB
OVBC
OVBC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
OVBC
OVBC
Q4 25
$170.3M
Q3 25
$399.7M
$164.4M
Q2 25
$424.5M
$160.8M
Q1 25
$454.6M
$155.7M
Q4 24
$150.3M
Q3 24
$489.3M
$152.2M
Q2 24
$510.3M
$145.8M
Q1 24
$577.3M
$145.8M
Total Assets
LAB
LAB
OVBC
OVBC
Q4 25
$1.6B
Q3 25
$539.6M
$1.6B
Q2 25
$557.0M
$1.5B
Q1 25
$579.6M
$1.5B
Q4 24
$1.5B
Q3 24
$681.5M
$1.5B
Q2 24
$708.7M
$1.4B
Q1 24
$777.7M
$1.4B
Debt / Equity
LAB
LAB
OVBC
OVBC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
OVBC
OVBC
Operating Cash FlowLast quarter
$-22.2M
$18.1M
Free Cash FlowOCF − Capex
$-23.1M
$17.0M
FCF MarginFCF / Revenue
-118.1%
105.2%
Capex IntensityCapex / Revenue
4.5%
6.4%
Cash ConversionOCF / Net Profit
4.57×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M
$26.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
OVBC
OVBC
Q4 25
$18.1M
Q3 25
$-22.2M
$5.3M
Q2 25
$-20.7M
$4.5M
Q1 25
$-30.3M
$496.0K
Q4 24
$13.1M
Q3 24
$-27.9M
$5.6M
Q2 24
$-39.0M
$4.2M
Q1 24
$-62.5M
$928.0K
Free Cash Flow
LAB
LAB
OVBC
OVBC
Q4 25
$17.0M
Q3 25
$-23.1M
$5.0M
Q2 25
$-22.6M
$4.4M
Q1 25
$-35.3M
$138.0K
Q4 24
$11.7M
Q3 24
$-30.1M
$5.4M
Q2 24
$-41.0M
$3.9M
Q1 24
$-63.3M
$234.0K
FCF Margin
LAB
LAB
OVBC
OVBC
Q4 25
105.2%
Q3 25
-118.1%
30.4%
Q2 25
-103.6%
25.1%
Q1 25
-86.6%
0.8%
Q4 24
68.7%
Q3 24
-136.4%
35.1%
Q2 24
-182.2%
26.3%
Q1 24
-138.9%
1.6%
Capex Intensity
LAB
LAB
OVBC
OVBC
Q4 25
6.4%
Q3 25
4.5%
2.1%
Q2 25
8.7%
0.6%
Q1 25
12.4%
2.1%
Q4 24
8.4%
Q3 24
10.2%
1.2%
Q2 24
8.6%
2.2%
Q1 24
1.7%
4.7%
Cash Conversion
LAB
LAB
OVBC
OVBC
Q4 25
4.57×
Q3 25
1.75×
Q2 25
1.06×
Q1 25
0.11×
Q4 24
5.21×
Q3 24
2.06×
Q2 24
1.41×
Q1 24
0.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

OVBC
OVBC

Segment breakdown not available.

Related Comparisons